Clinical Trials
15 trialsNCT01875601 2026-05-22
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06239220 2026-02-27
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT01385423 2025-07-24
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT05304754 2025-04-06
PHINK
Instituto de Investigación Hospital Universitario La Paz
Phase 1/2 Active not recruiting
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT01572493 2023-03-06
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04185220 2023-01-04
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03905135 2022-09-13
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04150562 2022-05-17
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03759184 2022-03-22
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02395822 2018-02-20
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01727076 2017-09-15
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01369888 2015-01-27
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated